Bacteriophages for prophylaxis and therapy in cattle, poultry and pigs
Bacteriophages for prophylaxis and therapy in cattle, poultry and pigs
复制标题
DOI：
10.1017/s1466252308001576
复制
发表时间：
2008-12-01
影响因子：
2.5
通讯作者：
Donoghue, A. M.
中科院分区：
文献类型：
--
作者：
Johnson, R. P.;Gyles, C. L.;Donoghue, A. M.
强毒(裂解)噬菌体(噬菌体)在预防和治疗新生牛犊、羔羊和猪的产肠毒素大肠杆菌感染中的成功应用，促使人们研究噬菌体疗法在食用动物中的其他应用。虽然结果差异很大，但一些结果表明，噬菌体疗法对鸡、牛犊和粪坑中的沙门氏菌和大肠杆菌感染，以及对鸡的食源性病原体沙门氏菌和空肠弯曲菌以及牛的O157：H7大肠杆菌的控制有潜在的帮助。然而，需要更严格和更全面的研究来确定噬菌体疗法的真正潜力。特别的挑战包括噬菌体的选择和特性，实用的给药模式，以及保持给药噬菌体生存能力的配方的开发。此外，对噬菌体疗法的有意义的评估将需要密切代表预期用途的动物研究，并将包括通过调查抗噬菌体细菌的出现和特征。此外，有效的使用还需要了解地方性和治疗性噬菌体的生态和动态，以及它们与农场环境中的目标细菌的相互作用。即使噬菌体疗法的潜力被实现，它的采用也将取决于它的有效性和相对于其他干预措施的互补性。另一个潜在挑战将是监管部门的批准。
The successful use of virulent (lytic) bacteriophages (phages) in preventing and treating neonatal enterotoxigenic Escherichia coli infections in calves, lambs and pigs has prompted investigation of other applications of phage therapy in food animals. While results have been very variable, some indicate that phage therapy is potentially useful in virulent Salmonella and E. coli infections in chickens, calves and pits, and in control of the food-borne pathogens Salmonella and Campylobacter jejuni in chickens and E. coli O157:H7 in cattle. However, more rigorous and comprehensive research is required to determine the true potential of phage therapy. Particular challenges include the selection and characterization of phages, practical modes of administration, and development of formulations that maintain the viability of phages for administration. Also, meaningful evaluation of phage therapy will require animal studies that closely represent the intended use, and will include through investigation of the emergence and characteristics of phage resistant bacteria. As well, effective use will require understanding the ecology and dynamics of the endemic and therapeutic phages and their interactions with target bacteria in the farm environment. In the even that the potential of phage therapy is realized, adoption will depend on its efficacy and complementarity relative to other interventions. Another potential challenge will be regulatory approval.